GERN · Program file
imetelstat
When did Geron Corporation say imetelstat results would come?
On , Geron Corporation wrote in its SEC Form 10-Q: “Based on our current planning assumptions for event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028.” (Source)
Days left in the window the company stated: 73 · company’s wording: “second half of 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- imetelstat
- Other names in filings
- RYTELO · IMpactMF
- Indication in the filing
- intermediate-2 or high-risk myelofibrosis after relapse or refractory response to a JAK inhibitor
- Trials named in the same filing
- None listed
- Latest timing wording
- “Based on our current planning assumptions for event (death) rates in the trial, we expect the interim analysis for OS in IMpactMF may occur in the second half of 2026 and the final analysis may occur in the second half of 2028.”
- Source
- 10-Q · filed · SEC accepted · accession 0000886744-26-000037 · SEC original
- Last checked
Program GERN-imetelstat.